| Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| 13F holders | Current |
|---|---|
| Total holders | 29 |
| Opened positions | 15 |
| Closed positions | 13 |
| Increased positions | 2 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 541.96 bn |
| Total shares | 45.89 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| General Atlantic | 7.53 mm | $141.59 bn |
| venBio Partners | 4.29 mm | $80.64 bn |
| venBio Global Strategic Fund III | 4.26 mm | $49.56 mm |
| Viking Global Investors | 3.65 mm | $68.68 bn |
| LSP V Cooperatieve U.A. | 3.61 mm | $51.91 mm |
| VR Adviser | 3.40 mm | $63.84 bn |
| Venrock Healthcare Capital Partners III | 3.40 mm | $0.00 |
| Foresite Capital Fund IV | 3.25 mm | $0.00 |
| Bain Capital Life Sciences Fund | 1.97 mm | $56.18 mm |
| Commodore Capital | 1.81 mm | $34.03 bn |
